Physician profile
Sara E Chance
NPI 1902271711
$2,100.30
in general payments reported to CMS, 2019-2025
25 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $268 · 2022: $368 · 2023: $330 · 2024: $756 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.59 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $404.69 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $373.59 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $215.26 | 2021-2024 | Verquvo |
| Medtronic, INC. | $182.82 | 2022-2024 | Linq II |
| Sanofi-Aventis U.S. LLC | $155.82 | 2021-2024 | |
| Boston Scientific Corporation | $149.88 | 2023-2025 | Watchman Flx, Resonate El Icd Vr, Farapulse |
| Cvrx, INC. | $102.48 | 2021-2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $71.32 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.52 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $42.28 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $40.80 | 2024-2025 | Camzyos |
| Genzyme Corporation | $34.17 | 2025 | |
| Amgen INC. | $34.05 | 2021-2022 | |
| Philips North America LLC | $30.87 | 2024 | (Ck4) Mcot |
| Actelion Pharmaceuticals US, INC. | $23.40 | 2024 | Uptravi, Opsumit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $22.67 | 2025 | Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $21.26 | 2024 | Arcalyst |
| Elutia, INC. | $21.17 | 2024 | Ecm Patch,Pouch |
| Convatec INC. | $20.20 | 2025 | |
| Atricure, INC. | $18.22 | 2024 | |
| Vivus LLC | $18.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.40 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $15.72 | 2023 | Inpefa |
| Innovation Technologies INC | $15.04 | 2025 | Irrisept |
| Janssen Pharmaceuticals, INC | $14.67 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Chance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.